Seoul, South Korea Two of South Korea’s leading biotech innovators, CoresteamChemo and ATG Lifetech, have announced a strategic partnership aimed at delivering next-generation, precision-driven preclinical research solutions to the global pharmaceutical and biotech industries.
The collaboration brings together CoresteamChemo’s two-decade expertise in GLP-certified toxicology and pharmacokinetics with ATG Lifetech’s cutting-edge transcriptome analytics and organoid modeling capabilities. Their joint mission? To offer high-content, biologically reliable preclinical services across Asia, Europe, and the U.S.—raising the bar for global drug development.
🚀 What the Partnership Will Deliver
The duo plans to co-develop a range of innovative tools, including:
- A transcriptomics-based drug evaluation platform for predicting drug efficacy and safety.
- Organoid models of key organs like the heart, liver, and blood-brain barrier, offering 5x greater predictive accuracy than traditional 2D cell cultures.
- Advanced tumorigenesis screening tools to differentiate true vs. false positives in cancer studies.
- Integrated support to help biotech clients navigate complex FDA and EMA regulatory pathways.
- These offerings aim to bridge critical gaps in preclinical drug development, delivering faster, more accurate, and more reliable data for pharmaceutical innovators.
🌍 Going Global
As part of their expansion, the companies will unveil their joint efforts at a major international toxicology and preclinical science conference in Q4 2025. They also plan to roll out global service lines tailored to clients seeking next-level testing solutions rooted in biological relevance and regulatory compliance.
A CoresteamChemo spokesperson shared:
“ATG Lifetech’s breakthrough transcriptome and organoid platforms will significantly enhance the scientific strength of our preclinical offerings. Together, we are positioning ourselves as a globally trusted CRO partner with best-in-class biological applications and regulatory readiness.”
🔬 About the Companies
CoresteamChemo: A full-service, GLP-compliant preclinical CRO with AAALAC-certified facilities and strong partnerships across the U.S., Europe, and Asia. Known for its depth in toxicology and regulatory consulting.
ATG Lifetech: A biotechnology firm at the forefront of transcriptome analytics and organoid research, playing a key role in South Korea’s government-backed biopharma ecosystem and known for collaborations with global players like ACROBiosystems.
As the biotech world moves rapidly toward more personalized, biologically informed therapies, this partnership marks a timely and powerful alignment of science, strategy, and global ambition.
Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com